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Abstract
Background: Globally, almost 40% of tuberculosis (TB) patients remain undiagnosed, and those that are diagnosed
often experience prolonged delays before initiating correct treatment, leading to ongoing transmission. While there
is a push for active case finding (ACF) to improve early detection and treatment of TB, there is extremely limited
evidence about the relative cost-effectiveness of different ACF implementation models. Cambodia presents a
unique opportunity for addressing this gap in evidence as ACF has been implemented using different models, but
no comparisons have been conducted. The objective of our study is to contribute to knowledge and methodology
on comparing cost-effectiveness of alternative ACF implementation models from the health service perspective,
using programmatic data, in order to inform national policy and practice.
Methods: We retrospectively compared three distinct ACF implementation models - door to door symptom
screening in urban slums, checking contacts of TB patients, and door to door symptom screening focusing on rural
populations aged above 55 - in terms of the number of new bacteriologically-positive pulmonary TB cases
diagnosed and the cost of implementation assuming activities are conducted by the national TB program of
Cambodia. We calculated the cost per additional case detected using the alternative ACF models.
Results: Our analysis, which is the first of its kind for TB, revealed that the ACF model based on door to door screening
in poor urban areas of Phnom Penh was the most cost-effective (249 USD per case detected, 737 cases diagnosed),
followed by the model based on testing contacts of TB patients (308 USD per case detected, 807 cases diagnosed),
and symptomatic screening of older rural populations (316 USD per case detected, 397 cases diagnosed).
Conclusions: Our study provides new evidence on the relative effectiveness and economics of three implementation
models for enhanced TB case finding, in line with calls for data from ‘routine conditions’ to be included in disease
control program strategic planning. Such cost-effectiveness comparisons are essential to inform resource allocation
decisions of national policy makers in resource constraint settings. We applied a novel, pragmatic methodological
approach, which was designed to provide results that are directly relevant to policy makers, costing the interventions
from Cambodia’s national TB program’s perspective and using case finding data from implementation activities, rather
than experimental settings.
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Background
Tuberculosis (TB) control remains a critical global chal-
lenge, becoming the leading cause of death from an
infectious disease in 2014. TB principally affects adults
in lower income countries, with 10.4 million new cases
estimated in 2015, of which more than half occurred in
people living in South-East Asia and Western Pacific re-
gions [1]. The Directly Observed Therapy Short-course
(DOTS) strategy to control TB was launched by the
World Health Organisation (WHO) in the early 1990’s
and was based on the premise that early detection and
treatment of new cases would prevent spread and reduce
the burden of disease. Global targets for the proportion
of new TB cases detected and treated successfully under
DOTS were set at 70 and 85% respectively. Despite
decades of investment towards these targets and 100%
DOTS coverage by 2004 [2], early case finding has been
a key challenge for TB program implementers. Currently,
an estimated 37% of TB patients globally remain undiag-
nosed or are not reported [1], and prolonged delays to
diagnosis are reported among some patients who do even-
tually access DOTS services. In recent years, the WHO
has raised concerns that the impact of current interven-
tions to improve early detection of TB may have been
saturated [3].
It is indeed likely that the current DOTS passive case
finding (PCF) strategy, which relies on patients present-
ing to the health facility for screening of their own
accord, has limitations in contexts where primary health
services are weak and awareness of TB is low; evidence
from a multi-country analysis indicated that DOTS pro-
grams may have no impact on improving case detection
[4]. PCF approaches may be resulting in both missed
diagnoses and delayed diagnosis, leading to transmission
of infection, which would be consistent with the small
(1–2% per annum) observed annual decline in incidence
of TB [5, 6]. At the current rate of decline in incidence,
it will take more than 150 years to meet the WHO
targets of reducing TB deaths by 95% and incidence by
90%, compared to 2015. In light of this, there is a push
for new models of case finding – collectively referred to
as Active Case Finding (ACF) approaches- which involve
specific out-reach activities by the health system and its
staff, in order to identify and test patients who are either
symptomatic or considered to be at higher risk of having
TB [7, 8]. The advantages of ACF include not only that
it potentially identifies TB cases which would not have
been diagnosed without the intervention, but may also
identify cases at an earlier stage than if relying on PCF
alone, thereby reducing transmission [9].
Although referred to using the same terms, numerous
different ACF implementation models exist, ranging from
population-wide screening to targeted case-finding in
high-risk groups [10]. Compared to PCF, ACF requires
higher investment and more human resources from
National TB Programs, which is a major concern in
resource-constrained settings [9]. Reviews of studies have
shown that the mode of implementation of TB control
activities has a large impact on cost-effectiveness, and
researchers have highlighted the need for comparisons of
different health service delivery models to inform planning
and expansion of programmatic approaches to TB control.
This is particularly true for ACF interventions. While glo-
bally there is some research comparing ACF implementa-
tion models and yields [11, 12], with a study in Zimbabwe
finding that 77% of symptomatic, smear-positive study
participants had their first investigation for TB through
community-based ACF [12], there is very limited informa-
tion about relative cost-effectiveness of different ACF
strategies. A review of over one hundred ACF publications
found that no studies conducted a cost effectiveness
analysis using established guidelines [13].
Cambodia presents a unique opportunity for addressing
this gap in evidence on relative cost-effectiveness of alter-
native ACF implementation models. The country has one
of the highest TB incidence rates in the region, at 380 per
100,000 population and approximately 40% of smear-
positive patients remain undiagnosed [2]. Many different
ACF interventions have been piloted in Cambodia since
2010 [14–17], and studies thus far have only looked at the
cost effectiveness of a single ACF strategies [15, 18]. The
National Center for Tuberculosis and Leprosy Control in
Cambodia (CENAT), which is the government body
responsible for resource allocation decisions on TB con-
trol activities, highlighted the urgent need to compare
ACF strategies in order to assess which models identify
the largest number of new TB cases per unit of invest-
ment. In close collaboration with, and in order to inform,
CENAT policy makers, we conducted a pragmatic com-
parison of the cost effectiveness of three large-scale ACF
programs from a health system perspective. These
programs have been piloted in Cambodia and decisions
on scale up need to be made.
Methods
We compared three ACF programs using retrospective
data on case-finding during the implementation period
of the pilot program, and primary data collected on costs
of implementation, as described below.
Selection of ACF models for comparison
To initiate the cost-effectiveness comparison, we first
compiled a list of all ACF interventions implemented in
Cambodia over the past 5 years, through discussions
with officials at CENAT and the Cambodia WHO office
which had held a meeting of all ACF implementing
agencies, supplemented with searches of peer reviewed
literature, grey literature and organizational websites.
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We identified nine different approaches to delivering
ACF services across the country by CENAT and various
non-governmental organisations (NGOs): symptom
screening in prisons; testing contacts of TB patients;
testing patients with HIV; door to door symptom
screening in urban slums; symptom screening focusing
on elderly members of the community; and using commu-
nity based volunteers for identification of symptomatic
patients in rural areas.
For this study, we selected ACF interventions meeting
the following criteria, to allow for a comparison across
implementation approaches: large-scale (covering more
than three districts), primarily targeting adults in the
community, seeking to diagnose bacteriologically con-
firmed (B+) cases using smear-microscopy or Xpert
MTB/RIF (GeneXpert) and implemented for a similar
time period (10–14 months). We identified three distinct
ACF interventions implemented by different public
health organisations for inclusion in the analysis. Imple-
mentation approaches applied to deliver ACF services are
summarized below and in Table 1. All interventions were
initiated within a similar timeframe (2012–2013) and were
funded through the same mechanism (TB REACH). They
therefore followed similar reporting and compliance re-
quirements and were independently assessed by an
outside agency selected by the funder [19, 20].
Implementation aspects of ACF models compared
(1)Screening contacts of index cases (CENAT) [15]
The national TB program in Cambodia, CENAT con-
ducted an ACF program for 10 months (2012–2013) in 15
operational districts (ODs), using a neighborhood and
household contact tracing strategy. Any smear-positive TB
cases registered for treatment during the preceding 2 years
were located and their household contacts were referred
for chest X-Ray (CXR) testing irrespective of presence or
absence of symptoms. In addition, people living in the
neighbourhood of a confirmed TB case who demonstrated
symptoms consistent with TB were referred for the same
CXR testing. Community health workers, known as
Village Health Support Group (VHSG), were responsible
for referring individuals for CXRs. Any person with an
abnormal CXR or with persistent symptoms suggestive of
TB and a normal CXR underwent GeneXpert sputum
testing alone in order to identify B+ TB cases.
(2)Screening of urban poor (HOPE) [14]
Sihanouk Hospital of Hope (HOPE) conducted ACF
over a 14-month period (2012–2013), covering four ODs
within Phnom Penh city. They targeted poor urban com-
munities, which had a presumed higher prevalence of TB
related to socioeconomic factors and reduced access to
TB treatment. VHSG, managed by salaried ‘TB workers’,
conducted verbal door to door symptom screening and
sputum samples were requested from those reporting TB
symptoms. Sputum samples were transported for smear-
microscopy testing at referral hospitals and the HOPE
hospital in Phnom Penh. GeneXpert and sputum culture
were utilized when subjects were suspected of having HIV
co-infection, being at higher risk of multi drug-resistant
(MDR) TB and in those who were negative on microscopy
but had persisting symptoms.
(3)Targeted screening in older rural population (CATA)
The Cambodia Anti-Tuberculosis Association (CATA)
organisation conducted a 12 month ACF program
(2013–2014) covering five ODs. They focused, non-
exclusively, on people aged 55 years or older, due to the
known higher TB case notification rates in this age
group [21]. CATA staff and OD TB focal persons
worked with health center staff and VHSG to conduct
verbal symptom screening and coordinate CXR and
Table 1 Summary of TB Active Case Finding (ACF) strategies
CENAT HOPE CATA
Target groups Neighbourhood and household
contacts of TB cases (registered
within the last 2 years)
Populations in poor urban settlements,
Phnom Penh
Older age (>55 yrs. old) and vulnerable
groups
Key activities • Community health worker visited
homes of TB patients registered
within last 2 yrs.
• TB-officers and village-health-volunteers
performed door to door symptom screening
of 315,874 people
• Door to door screening of 68,486
people, focusing on older patients
• 33,029 household contacts and
‘neighbourhood contacts’ screened
using CXR
• 12,201 symptomatic patients identified • 11,995 symptomatic patients referred
for testing and provided transport
costs if required
• 3632 patients with abnormal CXR
had a GeneXpert sputum test
• 10,301 symptomatic patients tested with
(LED fluorescence) microscopy
• 11,650 underwent CXR screening
• 1894 patient underwent GeneXpert testing • 2518 had GeneXpert testing
Operational Districts 15 4 5
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GeneXpert testing in mobile units. Symptomatic patients
attending screening at the health centres initially had
CXRs and when features suggestive of TB were found,
underwent GeneXpert testing. Patients identified with
symptoms in remote areas who could not easily visit
health centres were tested directly with GeneXpert.
Calculation of effectiveness
We defined the effectiveness of ACF interventions in
terms of the number of new, adult TB cases diagnosed.
To allow a comparison between interventions, we
applied a standard definition to assess the number of
new cases diagnosed: confirmed B+ cases based on
smear-microscopy or GeneXpert testing, pulmonary TB,
aged 15 or above.
We extracted data from internal reports, published pa-
pers, as well the raw data on case finding activities from
each program. Published research papers were available
for two of the ACF strategies (HOPE [14] and CENAT
[15]); the authors were contacted and they provided
further reports as well as raw data for analysis. The
unpublished reports examined included internal project
narrative documents and results data, standardized TB
REACH annual reports for each intervention and in-
ternal budget information. Discussions were held with
implementing staff for each intervention in person and
on the phone to fully understand the implementation
approach, before and after the data extraction process.
A standardized data extraction tool was used to
extract data about the duration of activities, area of
coverage and number of eligible B+ cases diagnosed by
ACF intervention.
Costing of ACF implementation activities
For each ACF project, we gathered detailed information
about the activities conducted to diagnose new TB cases,
including trainings and preliminary meetings prior to
initiating ACF activities, in order to estimate costs of
implementing the same activities from the health service
(CENAT’s) perspective. First, interviews were conducted
with key implementation staff involved in the ACF
activities of each organization (two per organization) to
understand resources used, applying a standardised data
collection template (Table 2); this was supplemented
with data from official records and reports (including
TB REACH yearly reports, internal reports and budgets).
After resource information was gathered, follow up
interviews were conducted with key personnel from
each organisation to clarify and review the resourcing
information compiled.
We then shared data on all the resources required by
each ACF intervention with CENAT, who supplied their
cost estimates for each type of resource, according to
their budget predictions for the coming year (2016), this
method, along with the exclusive use of USD dollars,
avoided any need to adjust figures according to historic
inflation or exchange rates, respectively.
Once we had a unit cost for all of the resources used
and activities conducted we calculated the overall costs
for each of the three strategies, from the perspective that
activities would be conducted by CENAT as part of their
programmatic strategy for TB control. If there were
additional activities or trainings that CENAT would in-
sist on as part of any ACF strategy they conducted - for
example, training relevant staff on GeneXpert equip-
ment - this was added to the budget for HOPE and
CATA’s activities.
In addition to the costs incurred during the data col-
lection period, the cost of all trainings and preliminary
meetings for each program were calculated and in-
cluded. The preparation and post data collection
activities were not included as each organisation took
variable lengths of time with overlapping resources for
other activities, making the calculation of accurate times
and costs for each activity difficult.
Cost effectiveness comparison
We sought to estimate the cost per additional B+ case
diagnosed for the three different ACF strategies, using a
health system cost perspective based on the assumption
that the ACF strategies would be implemented by
CENAT. We assessed cost-effectiveness using the
Table 2 Breakdown of cost categories used to analyse the ACF strategies
Costing Category Description
Staff salaries Staff hired specifically for the project.
Per diem payments All per diems payments for project related scoping, training and field trips. Usually per diems cover
all food, accommodation and travel and CENAT supply a lower rate for travel local within Phnom Penh
than overnight stays away.
Trainings and meetings All training sessions and meetings required for the ACF program, including room hire, materials and preparation.
Equipment Equipment for each program was listed and compared to the resources CENAT currently has access to; any
additional equipment (eg: generators) was costed for.
Transport Staff, patients or sputum sample transport related to diagnosis of TB.
Consumables Consumables included items such as petrol, testing materials (X-ray film, GeneXpert cartridges, microscopy reagents)
and mobile phone credit.
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standard approach used by researchers and funders such
as TB REACH, defining the cost per TB case detected as
the total cost of activities related to diagnosis divided by
the total number of TB cases diagnosed [22].
Assumptions
The method of analysis employed in this study as-
sumes that the effectiveness achieved for each dollar
spent is comparable between the programs, meaning
there is an assumption of equivalent efficiency across
the three implementing groups. A further assump-
tion made in the comparison, is that the cases
detected would not have been detected had the ACF
activities not taken place. It should be noted that
due to the different contexts of each strategy the
consequences of this assumption is likely to vary
between the programs.
Results
Our comparison of three distinct ACF models in
Cambodia revealed that the cost per case detected was
249 USD, 308 USD and 316 USD, for the HOPE,
CENAT and CATA ACF models, respectively (Table 3).
HOPE’s program, working in poor urban areas of Phnom
Penh, was the most cost-effective of the three, by a small
margin, followed by the model of testing contacts of TB
patients (CENAT) and the CATA model focusing on
older rural populations.
CENAT’s ACF activities involved providing CXRs to
33,029 people and diagnosed 807 B+ patients. HOPE
tested 10,301 symptomatic individuals using sputum
microscopy and 1894 with GeneXpert, leading to 737
confirmed B+ cases. Finally, CATA focused on older
rural subjects, providing 11,650 CXRs after verbal symp-
tom screening with 2518 going onto have GeneXpert
testing, leading to 397 confirmed B+ cases.
The costing analysis, summarized in Table 4, showed
that the contact tracing ACF model implemented by
CENAT had a total cost of USD 248,222, while HOPE
and CATA’s models cost 183,180 and 125,297 respect-
ively. Distribution of costs varied between ACF
models, with HOPE spending a higher proportion on
salaries than the other organizations, while CATA and
CENAT spent more on consumables. HOPE used some of
its budget on equipment not routinely supplied by
CENAT, which included mobile phones for their TB
workers and cool boxes for sputum transportation.
Discussion
The results show that despite differences in implementation
models and populations, cost-effectiveness of the three in-
terventions was relatively similar, with HOPE being the
most cost-effective at less than 250 USD per new case diag-
nosed. The two rural programs of CENAT and CATA,
which applied more costly diagnostic protocols involving
chest x-rays, had very similar cost-effectiveness results, at
USD 308 and 316 per case detected respectively.
Published ACF costs, per case detected, show that a
wide range exists globally, from USD 108 in Cambodia
(2010) [18] to USD 444–1493 in South Africa (2015) [23]
and USD 1581–4000 in Russia (1995) [24]. TB REACH
guidance suggests that the cost per additional case (those
TB cases detected by the intervention above the local
historical trend) detected and treated, for interventions
they fund should be up to USD 350, however, this is a
different measure to the costing in our study [1, 22].
Increased case detection and high treatment success
rates are the cornerstones of global TB control policy [1]
and as one of the top 22 high burden countries, Cambodia
has implemented multiple strategies to improve its case
detection rate. This is the first cost-effective analysis dir-
ectly comparing alternative models of ACF in Cambodia,
and, to our knowledge, no similar comparison has been
conducted in other high TB burden countries.
Table 3 Cost effectiveness summary
CENAT HOPE CATA
Intervention months [dates] 10 [Feb 2012 – Dec 2012] 14 [Feb 2012 – Mar 2013] 12 [Mar 2013 – Mar 2014]
Total B+ patients diagnosed 807 737 397
B+ patients diagnosed per month 80.7 52.6 33.1
Total cost (USD) 248,222 183,180 125,297
Cost per month (USD) 24,822 15,265 17,899
Cost per new B+ case diagnosed (USD) 308 249 316
Table 4 Cost breakdown of each ACF intervention
Budget Categories CENAT HOPE CATA
Staff salaries 32,700 (13) 85,060 (46) 19,880 (16)
Per diem payments 22,572 (9) 31,112 (17) 35,420 (28)
Trainings and meetings 61,474 (25) 20,255 (11) 11,502 (9)
Equipment 0 (0) 1360 (1) 0 (0)
Transport 840 (0) 10,940 (6) 3185 (3)
Consumables 130,636 (53) 34,453 (19) 55,310 (44)
TOTAL /USD 248,222 183,180 125,297
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Our study provides timely information in light of calls
for cost-effectiveness data from ‘routine conditions’ to be
included when programmatic recommendations for TB
diagnosis are made [25]. Such cost-effectiveness informa-
tion is essential to inform resource allocation decisions of
national policy makers. Our method of analyzing the three
ACF strategies was designed to provide data that is
directly relevant to policy makers, taking a pragmatic ap-
proach towards costing the interventions from Cambodia’s
national TB program’s (CENAT’s) perspective and using
case finding data from program activities, rather than
experimental settings. It is important to consider that our
analysis, by design, compares heterogeneous ACF models
with different population characteristics, the most import-
ant being a likely variable TB prevalence [22]. Different
screening algorithms were used and the urban poor
screening by HOPE used cheaper diagnostic techniques
compared to the other two; thus the logistics and costs of
each project varied. HOPE also focused exclusively on
urban areas where the higher population density meant
that larger numbers of people could be screened within a
smaller geographical area.
A potential limitation relates to the estimation of costs
by CENAT and an assumption that scale up of CATA
and HOPE strategies by CENAT will be possible and
provide the same efficiency, without substantial extra in-
vestment in the current services and health centres.
However, there were also advantages to the method
employed for cost calculations, with the unit costs being
standardized according to national program estimates.
We acknowledge that reductions in patient costs owing
to outreach activities are not accounted for, and that the
cost-effectiveness comparison does not consider equity
and accessing of hard to reach populations, which may
justify a higher cost per case detected. Finally, we
recognize that wider questions regarding ACF itself still
remain and highlight that ACF strategies will only be
effective if cases are identified early such that onward
transmission is prevented. Thus, before launching into
large ACF programs in resource-limited settings, prag-
matic comparisons of different ACF models – looking
not only at cost per case detected as we have done but
also at forecasts of long term impact on TB incidence-
are required to inform resource allocation decisions.
Conclusion
Alternative ACF implementation models for TB are be-
ing introduced in numerous resource-constraint settings,
but evidence on relative cost-effectiveness, which is
essential to inform resource allocation decisions of
national policy makers, is lacking. We applied a novel,
pragmatic methodological approach to compare the
cost-effectiveness of three ACF implementation models
that had been implemented between 2012 and 2013 in
Cambodia, allowing the models to be ranked in terms of
potential to identify the largest number of new
bacteriologically-positive TB cases per unit of invest-
ment. We found that implementation of ACF activities
in urban areas was slightly more cost-effective than in
rural areas, and that the pragmatic cost-effectiveness
assessment approach provided information that was
called for by local policy makers.
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